Eisai Co Ltd (ESALF) Stock Price, Trades & News

Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Financial Strength

7/10

Name	Current	Vs Industry
Cash-To-Debt	1.32
Equity-to-Asset	0.62
Debt-to-Equity	0.21
Debt-to-EBITDA	1.94
Interest Coverage	8.27
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.8	Distress Grey Safe
Beneish M-Score	-2.5	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

5/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	4.1
	3-Year EBITDA Growth Rate	3.8
	3-Year EPS without NRI Growth Rate	-10.9
	3-Year Book Growth Rate	4.6
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	20.83
	Future 3-5Y Total Revenue Growth Rate Estimate	5.96

Momentum Rank

4/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	68.58
	9-Day RSI	43.52
	14-Day RSI	34.43
	3-1 Month Momentum %	-8.5
	6-1 Month Momentum %	-3.45
	12-1 Month Momentum %	-4.48

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.24
	Quick Ratio	1.48
	Cash Ratio	0.72
	Days Inventory	450.81
	Days Sales Outstanding	100.84
	Days Payable	159.06

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	4.07
	Dividend Payout Ratio	1.14
	Forward Dividend Yield %	4.05
	5-Year Yield-on-Cost %	4.07
	3-Year Average Share Buyback Ratio	0.6
	Shareholder Yield %	1.35

Profitability Rank

6/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	76.83
	Operating Margin %	5.35
	Net Margin %	4.67
	EBITDA Margin %	11.62
	FCF Margin %	2.48
	OCF Margin %	7.36
	ROE %	4.47
	ROA %	2.69
	ROIC %	3.31
	3-Year ROIIC %	-2.33
	ROC (Joel Greenblatt) %	15.36
	ROCE %	5.34
	Years of Profitability over Past 10-Year	10
	Moat Score	6
	Tariff Resilience Score	8

GF Value Rank

8/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	28.47
	Forward PE Ratio	18.85
	PE Ratio without NRI	28.47
	Shiller PE Ratio	5.89
	Price-to-Owner-Earnings	48.72
	PS Ratio	1.33
	PB Ratio	1.22
	Price-to-Tangible-Book	1.99
	Price-to-Free-Cash-Flow	54.46
	Price-to-Operating-Cash-Flow	17.9
	EV-to-EBIT	18.9
	EV-to-Forward-EBIT	28.86
	EV-to-EBITDA	11.11
	EV-to-Forward-EBITDA	18.16
	EV-to-Revenue	1.29
	EV-to-Forward-Revenue	2.77
	EV-to-FCF	52.83
	Price-to-GF-Value	0.71
	Price-to-Projected-FCF	1.08
	Price-to-Median-PS-Value	1.31
	Price-to-Graham-Number	1.59
	Price-to-Net-Current-Asset-Value	5.19
	Earnings Yield (Greenblatt) %	5.29
	FCF Yield %	1.83
	Forward Rate of Return (Yacktman) %	-3.57

GF Value™: $35.06

ESALF

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with ESALF. Try a 7-Day Free Trial to check it out.

Eisai Co Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Eisai Co Ltd Stock Events

Financials Calendars

Event	Date	Price ($)
JPY 80.000000 Cash Dividend	2026-09-29	In 95 days
JPY 80.000000 Cash Dividend	2026-03-30	30.00 (+0.00%)
JPY 80.000000 Cash Dividend	2025-09-29	34.00 (+0.00%)
JPY 80.000000 Cash Dividend	2025-03-28	28.95 (+0.21%)
JPY 80.000000 Cash Dividend	2024-09-27	38.40 (+0.00%)

Show

Entries

Guru Commentaries on OTCPK:ESALF

No articles.

Press Release

	Subject	Date
	Eisai and CaringKind Launch New Initiative to Address Mealtime and Nutrition Needs for People Living with Alzheimer's Disease and Related Dementias	2026-06-01
	FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review	2026-01-25
	Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025	2025-12-01
	Eisai to Present Data on Lecanemab Continued Treatment, Subcutaneous Initiation Dosing, and Real-World Experience at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference	2025-11-18
	Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025	2025-09-08
	Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025	2025-09-03
	/U P D A T E -- Eisai Inc./	2025-09-02
	FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease	2025-08-29
	Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025	2025-07-30
	New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease	2025-07-30

10/Page

Articles on Eisai Co Ltd

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.